Post-Marketing Surveillance of Prazaxa® on the Long-term Use in Patients With Nonvalvular Atrial Fibrillation
Status:
Completed
Trial end date:
2016-08-02
Target enrollment:
Participant gender:
Summary
To investigate the safety and efficacy of long-term use of Prazaxa® Capsules in patients with
nonvalvular atrial fibrillation for preventing the occurrence of ischemic stroke or systemic
embolism (SEE).